Nontuberculous Mycobacterial (NTM) Infections Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies – RevImmune, Redhill Biopharma, Novoteris, Savara Pharma, Merck

Nontuberculous Mycobacterial (NTM) Infections Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - RevImmune, Redhill Biopharma, Novoteris, Savara Pharma, Merck

“Delveinsight Business Research LLP”
As per DelveInsight, the Nontuberculous mycobacteria (NTM) market dynamics are anticipated to transform in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of emerging therapies.

DelveInsight’s “Nontuberculous Mycobacterial (NTM) Infections Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Nontuberculous Mycobacterial (NTM) Infections market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Nontuberculous Mycobacterial (NTM) Infections market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Nontuberculous Mycobacterial (NTM) Infections Market

Nontuberculous Mycobacterial (NTM) Infections: An Overview

According to the American Lung Association, Nontuberculous mycobacteria (NTM) are naturally occurring organisms found in water and soil. NTM lung infection occurs when a person inhales an organism from their environment. Most people do not become ill, but for some susceptible individuals, the slowly progressive and destructive disease can occur.

NTM-PD (Nontuberculous mycobacterial pulmonary disease) is typically chronic, slowly progressive, and difficult to diagnose. It can present at any age but is most common in patients above the age of 50. 

As per Johnsons et al., although over 150 different species of NTM have been described, pulmonary infections are most commonly due to Mycobacterium avium complex (MAC), Mycobacterium kansasii, and Mycobacterium abscessus.

Nontuberculous Mycobacterial (NTM) Infections Market Key Facts

  • According to the study by Donohue and Wymer. 2016, “the overall average annual age-adjusted prevalence rate rose from 8.7 to 13.9 per 100,000 persons between the beginning and end of the surveillance period (2008–2013). The number of cases and case rate in the 50–80+-year age group was higher than in the 0–49-year age group.”

  • The total prevalent population of Nontuberculous Mycobacterial (NTM) Infections in the 7MM is expected to rise by 2032

  • Estimates show that the United States has the highest prevalent population of NTM infections, followed by Japan.

  • According to DelveInsight’s analysis, it has been observed that moderate NTM infection cases are more prominent in comparison to mild and severe cases.

  • A considerable number of prevalent cases of NTM infections were recorded in Japan, with 83,000 cases in 2021.

  • Among the EU-5 countries, Germany had the highest prevalent population of NTM infections, followed by France and the UK. On the other hand, Spain had the lowest prevalent population of NTM infections.

  • The recurrence rate of NTM infection after antibiotics therapy ranges from 20% to 45%. Patients experiencing relapse/recurrence after being treated with antibiotics are then considered for treatment with surgical interventions.  

Nontuberculous Mycobacterial (NTM) Infections Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Nontuberculous Mycobacterial (NTM) Infections market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Nontuberculous Mycobacterial (NTM) Infections market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Nontuberculous Mycobacterial (NTM) Infections Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Nontuberculous Mycobacterial (NTM) Infections Epidemiology Segmentation

  • Total prevalent cases of NTM infections

  • Diagnosed prevalent cases of NTM infections

  • Diagnosed prevalent cases of NTM infections by species

  • Diagnosed prevalent cases of NTM infections by severity

Nontuberculous Mycobacterial (NTM) Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nontuberculous Mycobacterial (NTM) Infections market or expected to get launched during the study period. The analysis covers the Nontuberculous Mycobacterial (NTM) Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Nontuberculous Mycobacterial (NTM) Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Nontuberculous Mycobacterial (NTM) Infections Market Will Evolve by 2032 @ 

https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market

As per DelveInsight, the Nontuberculous Mycobacterial (NTM) Infections market size is expected to increase during the forecast period owing to the launch of upcoming therapies.

Some of the key companies in the Nontuberculous Mycobacterial (NTM) Infections Market include:

  • RevImmune

  • Redhill Biopharma

  • Novoteris

  • Savara Pharma

  • Merck Sharp & Dohme Corp.

And many others.

Nontuberculous Mycobacterial (NTM) Infections Therapies covered in the report include:

  • Emend

  • CYT107 IL-7

  • RHB-204

  • Molgramostim

  • Nitric Oxide

  • Thiolanox

And many more.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Nontuberculous Mycobacterial (NTM) Infections Competitive Intelligence Analysis

4. Nontuberculous Mycobacterial (NTM) Infections Market Overview at a Glance

5. Nontuberculous Mycobacterial (NTM) Infections Disease Background and Overview

6. Nontuberculous Mycobacterial (NTM) Infections Patient Journey

7. Nontuberculous Mycobacterial (NTM) Infections Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Nontuberculous Mycobacterial (NTM) Infections Treatment Algorithm, Current Treatment, and Medical Practices

9. Nontuberculous Mycobacterial (NTM) Infections Unmet Needs

10. Key Endpoints of Nontuberculous Mycobacterial (NTM) Infections Treatment

11. Nontuberculous Mycobacterial (NTM) Infections Marketed Products

12. Nontuberculous Mycobacterial (NTM) Infections Emerging Drugs and Latest Therapeutic Advances

13. Nontuberculous Mycobacterial (NTM) Infections Seven Major Market Analysis

14. Attribute Analysis

15. Nontuberculous Mycobacterial (NTM) Infections Market Outlook (In US, EU5, and Japan)

16. Nontuberculous Mycobacterial (NTM) Infections Access and Reimbursement Overview

17. KOL Views on the Nontuberculous Mycobacterial (NTM) Infections Market

18. Nontuberculous Mycobacterial (NTM) Infections Market Drivers

19. Nontuberculous Mycobacterial (NTM) Infections Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Nontuberculous Mycobacterial (NTM) Infections Pipeline Insights

DelveInsight’s “Nontuberculous Mycobacterial (NTM) Infections Pipeline Insights, 2022” report outlays comprehensive insights into the present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial (NTM) Infections therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/